Inhibrx Biosciences (INBX) to Release Earnings on Tuesday

Inhibrx Biosciences (NASDAQ:INBX) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($2.08) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, April 3, 2026 at 5:00 PM ET.

Inhibrx Biosciences (NASDAQ:INBX) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($2.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.08) by ($0.03). On average, analysts expect Inhibrx Biosciences to post $105 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Inhibrx Biosciences Trading Down 11.2%

NASDAQ INBX opened at $58.39 on Friday. The stock has a market capitalization of $853.08 million, a price-to-earnings ratio of -6.46 and a beta of 1.50. The stock’s 50 day moving average price is $74.49 and its two-hundred day moving average price is $67.00. The company has a debt-to-equity ratio of 12.58, a quick ratio of 3.93 and a current ratio of 3.93. Inhibrx Biosciences has a 52 week low of $10.81 and a 52 week high of $94.57.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Inhibrx Biosciences in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Inhibrx Biosciences has an average rating of “Reduce”.

Institutional Trading of Inhibrx Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of INBX. Strs Ohio bought a new stake in Inhibrx Biosciences during the first quarter worth about $27,000. Persistent Asset Partners Ltd bought a new position in Inhibrx Biosciences in the fourth quarter valued at approximately $27,000. Public Employees Retirement System of Ohio acquired a new position in shares of Inhibrx Biosciences during the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets increased its position in shares of Inhibrx Biosciences by 71.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock worth $64,000 after purchasing an additional 789 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Inhibrx Biosciences during the 4th quarter worth approximately $66,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.